Servier’s vorasidenib proves efficacy in tumor growth reduction

New data shows Servier’s vorasidenib reduced tumour growth in a Phase III study in patients with IDH-mutant diffuse glioma.

In the newest analysis of the Phase III INDIGO trial (NCT04164901) vorasidenib demonstrated reduced tumour growth rate (TGR) and shrunk tumour volume, as measured by an independent radiology committee, while patients in the placebo arm saw continued growth in tumour volume.